Effect of Empagliflozin on Kidney Biochemical and Imaging Outcomes in Patients With Type 2 Diabetes, or Prediabetes, and Heart Failure with Reduced Ejection Fraction (SUGAR-DM-HF)

Circulation. 2022 Jul 26;146(4):364-367. doi: 10.1161/CIRCULATIONAHA.122.059851. Epub 2022 Jul 25.
No abstract available

Keywords: clinical trial; diabetes mellitus; empagliflozin; heart failure; kidney; magnetic resonance imaging; sodium-glucose transporter 2 inhibitors.

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Benzhydryl Compounds / pharmacology
  • Benzhydryl Compounds / therapeutic use
  • Diabetes Mellitus, Type 2* / drug therapy
  • Glucosides
  • Heart Failure* / diagnostic imaging
  • Heart Failure* / drug therapy
  • Humans
  • Kidney / diagnostic imaging
  • Prediabetic State* / drug therapy
  • Stroke Volume

Substances

  • Benzhydryl Compounds
  • Glucosides
  • empagliflozin